Comparative Pharmacology
Head-to-head clinical analysis: GLYCEROL PHENYLBUTYRATE versus SODIUM PHENYLACETATE AND SODIUM BENZOATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GLYCEROL PHENYLBUTYRATE versus SODIUM PHENYLACETATE AND SODIUM BENZOATE.
GLYCEROL PHENYLBUTYRATE vs SODIUM PHENYLACETATE AND SODIUM BENZOATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Glycerol phenylbutyrate is a prodrug that is metabolized to phenylacetate, which conjugates with glutamine to form phenylacetylglutamine. This compound is excreted by the kidneys, providing an alternative pathway for waste nitrogen excretion in patients with urea cycle disorders.
Sodium phenylacetate and sodium benzoate provide an alternative pathway for nitrogen excretion in patients with urea cycle disorders. Phenylacetate conjugates with glutamine to form phenylacetylglutamine, which is renally excreted, thereby eliminating waste nitrogen. Benzoate conjugates with glycine to form hippurate, which is also excreted in urine, removing ammonia precursors.
450-600 mg/m2/day orally in three divided doses, rounded to the nearest 100 mg; maximum 20 g/day.
Intravenous: Loading dose of 5.5 g/m² over 90-120 minutes, then continuous infusion of 5.5 g/m² over 24 hours.
None Documented
None Documented
Clinical Note
moderateGlycerol phenylbutyrate + Fesoterodine
"The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Glycerol phenylbutyrate."
Clinical Note
moderateGlycerol phenylbutyrate + Atorvastatin
"The risk or severity of adverse effects can be increased when Glycerol phenylbutyrate is combined with Atorvastatin."
Clinical Note
moderatePrednisolone + Glycerol phenylbutyrate
"The therapeutic efficacy of Glycerol phenylbutyrate can be decreased when used in combination with Prednisolone."
Clinical Note
moderate0.8–1 hours (glycerol phenylbutyrate); 1.2–1.5 hours (phenylacetate); clinical context: short half-life requires thrice-daily dosing
The terminal elimination half-life of phenylacetate is approximately 0.5-0.8 hours; however, its active conjugate phenylacetylglutamine has a half-life of about 1.2-1.5 hours. For benzoate, the half-life is approximately 0.5-1 hour. In the context of hyperammonemia treatment, the clinical effect correlates with the rapid formation of conjugates, and the half-life reflects quick clearance. In neonates or patients with renal impairment, half-life may be prolonged.
Renal: >90% as phenylbutyrate metabolites (mainly phenylacetylglutamine) within 24 hours; fecal: <1%
Sodium phenylacetate and sodium benzoate are primarily excreted renally. Phenylacetate is conjugated with glutamine to form phenylacetylglutamine, which is rapidly eliminated in urine. Benzoate is conjugated with glycine to form hippurate, also renally eliminated. Approximately 80-100% of the administered dose is recovered in urine as conjugates and minor metabolites. Fecal excretion is negligible (<5%).
Category C
Category C
Ammonia Detoxicant
Ammonia Detoxicant
Dexamethasone + Glycerol phenylbutyrate
"The therapeutic efficacy of Glycerol phenylbutyrate can be decreased when used in combination with Dexamethasone."